First-in-Human Study of EOS100850 in Patients With Cancer

clipboard-pencil

About the study

Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 as a Single Agent and in Combination with Pembrolizumab and/or Chemotherapy in Participants with Advanced Cancers.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  • For more information regarding participation in the Trial, please refer to your physician
  • Inclusion Criteria:


    1. Women and men ≥18 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
    2. Subject with histologically or cytologically confirmed advanced solid tumor for whom no standard treatment is further available.
    3. At least 4 weeks since any previous treatment for cancer
    4. Subject must consent to pretreatment and on treatment tumor biopsies
    5. Adequate organ and marrow function

    EXCLUSION CRITERIA

    Exclusion Criteria:


    1. Patients with primary brain tumors or primary tumors with central nervous system metastases as only location of disease. Controlled brain metastases are permitted
    2. Participants with second/other active cancers requiring current treatment
    3. Uncontrolled/significant heart disease
    4. Known History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)
    5. Active/uncontrolled autoimmune disease
    6. Active infection

    Other protocol defined inclusion/exclusion criteria could apply


    pin location

    Study Locations

    Enter your ZIP code/Postal code/PIN code to locate study sites near you:

    How to Apply


    Contact the study center to learn if this study is a good match for you.

    Study’s details


    Contition
    Solid Tumor, Adult
    Age (in years)
    18+
    Phase
    Phase 1
    Participants needed
    119
    Est. Completion Date
    Jul 31, 2024
    Treatment type
    Interventional

    Sponsor
    iTeos Therapeutics
    ClinicalTrials.gov identifier
    NCT03873883
    Study number
    IO-001

    Understanding Clinical Trials


    Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
    Vector

    Interested?

    Sign up to save your favorites, 
    receive newsletters, resources, and alerts 
    about clinical trials related to your conditions of interest.